Careers  |  Sign In  |  Register  |   Twitter

Latest in Diabetes

Sanofi has signed on with MannKind Corp. to purchase rights to Afrezza, the world’s first and only inhaled insulin product, an article published by Bloomberg News reports. MannKind Corp. will be paid $150 million up front, and as much as $925 million total for Afrezza, which received its FDA approval...
A two in one diabetes drug, created by Danish drug maker Novo Nordisk, has been recommended for approval by the European Union, a Reuters article reports. Clinical trials of the drug, Xultophy, have proven that simultaneous consumption of liraglutide (Victoza) and degludec — the components of Xultophy —...
For the 25 million American adults with diabetes, a new way to control blood sugar levels at mealtimes is right around the corner, an article published by CBS News reports. The FDA approved MannKind Corp.’s Afrezza, a fast-acting insulin product which comes in the form of a powder-filled cartridge....